Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 62

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 62
---
 ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business,
results of operations, financial condition and prospects.

Third parties may assert that
we are employing their proprietary technology without authorization. Generally, conducting preclinical and clinical trials or investigations
and other development activities in the United States is not considered an act of infringement. If our product candidate is approved by
the FDA, a third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we may believe that
patent claims or other intellectual property rights of a third party would not have a materially adverse effect on the commercialization
of our product candidates, we may be incorrect in this belief, or we may not be able to prove it in litigation. In this regard, patents
issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is “clear and convincing,”
a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Patent applications
can take many years to issue. There may be currently pending patent applications which may later result in issued patents that may be
infringed by our product candidates. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid,
not enforceable, exhausted, or not infringed by our activities. If any third-party patents, held now or obtained in the future by a third
party, were found by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules
used in or formed during the manufacturing process, or any final product or methods use of the product, the holders of any such patents
may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or
until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were
held by a court of competent jurisdiction to cover any aspect of our formulations, any combination therapies or patient selection methods,
the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained
a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may
not be available on commercially reasonable terms or